ST2-Modulating Agents for Lung Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung and liver fibrosis are inadequate in effectively modulating the ST2 pathway, leading to insufficient reduction of fibrosis and associated symptoms.
Innovation Solution
Administration of ST2-modulating agents, such as soluble ST2 polypeptides or fusion proteins, that bind to naturally occurring ligands like IL33, disrupting the interaction between ST2 and its ligands to treat fibrosis by reducing the activity or expression of ST2, thereby inhibiting fibrotic processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for lung and liver fibrosis are used, then fibrosis management is maintained, but the effectiveness in modulating the ST2 pathway and reducing fibrosis is insufficient
Solution Approach 1:
The patent introduces ST2-modulating agents as intermediary substances that specifically target the ST2 pathway. These agents act as mediators between the treatment system and the fibrotic process, binding to ST2 or its ligands to disrupt the fibrosis-promoting signaling pathway, thereby enhancing treatment effectiveness without affecting other physiological processes
2Reliability
If ST2-modulating agents are administered to reduce fibrosis, then fibrosis is reduced by 5-80%, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent extracts and isolates the specific ST2-modulating activity from complex natural sources or synthesizes it as discrete molecular entities. By taking out the essential fibrosis-modulating function into a purified, standardized agent form, the treatment achieves high efficacy while the agent's specificity allows for simplified dosing and administration protocols compared to broad-spectrum therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ST2-modulating agents significantly reduce lung and liver fibrosis by 5-80% and improve associated symptoms, offering a therapeutic benefit that can be used alone or in combination with other treatments, potentially reducing the dosage of secondary agents.
Implementation Method 1
administering to the subject an ST2-modulating agent, e.g., an agent that binds a naturally-occurring ST2 ligand, e.g., an agent that binds IL33
Data Source
AI summary
Methods and compositions for treating fibrosis are disclosed.